A method of administering a pharmaceutical agent to the circulatory system through the skin of a mammal may include the steps of loading a pharmaceutical agent in a transdermal patch, applying the transdermal patch to the skin of the mammal and releasing the pharmaceutical agent into the circulatory system at a rate of at least 0.001 micrograms per hour up to 50.0 micrograms per hour per kilogram of bodyweight of the mammal. The drug delivery system may comprise a transdermal patch loaded with the pharmaceutical agent. The patch may include a porous membrane and an outer impermeable cover defining a cavity therebetween. A plurality of drug delivery layers may be disposed between the porous membrane and the impermeable cover. A lipophilic/hydrophilic suspension may be disposed between the drug delivery layers.

A transdermal delivery system for systemic delivery of donepezil is described, where the system comprises an adhesive matrix drug reservoir layer comprised of a copolymer of acrylic acid/vinyl acetate, triethyl citrate, and donepezil base generated in situ by reaction of donepezil HCl and an alkaline salt. The system is provided for treatment of Alzheimer's disease, and achieves transdermal delivery of the therapeutic agent at steady state that is bioequivalent to administration of the therapeutic agent orally.

The present invention relates to a transdermal therapeutic system without a release-determining membrane for delivering scopolamine, comprising a skin contact layer, an active substance-containing reservoir layer, an active substance-impermeable backing layer, and optionally a protective layer which is detachable from the skin contact layer, wherein the skin contact layer is in direct contact with the active substance-containing reservoir layer. The skin layer or the skin layer and the reservoir layer may be equipped with adhesive strength-increasing additives, for example silicone oils. Furthermore, the system may be equipped with an active substance-free over-patch in order to ensure a sufficient adhesion onto the skin over the application duration. In comparison to comparable systems with a release-determining membrane, a similar bioavailability of the active substance was achieved, such that these systems are bioequivalent to the membrane-containing systems. The present invention additionally relates to the aforementioned transdermal therapeutic systems for use in the treatment of motion sickness and/or post-operative nausea as well as to methods for producing same.

A bandage device having a flexible body with a plurality of fluid reservoirs thereon each containing a liquid topical treatment therein. Mixing areas located between the respective fluid reservoirs on the bandage provide for mixing and formation of liquid mixtures of the respective liquid topical treatments flowing thereto from the respective fluid reservoirs located adjacent thereto. The liquid mixtures from the mixing areas when absorbed through the skin of a wearer of the bandage yield an enhanced synergistic effect exceeding that of the individual fluids such medications or essential oils.

A transdermal drug delivery patch includes a flexible base layer, and a plurality of microneedles disposed at one surface of the base layer and including a biodegradable polymer and a drug. Each of a plurality of microneedles is formed as a star-shaped pyramid including a plurality of protrusions extending in a radial direction, and a concave shape is formed between two protrusions adjacent along a circumferential direction among a plurality of protrusions.

A method of selecting a surfactant system suitable for infants and young children is disclosed.

A face mask or body cover assembly, including for lips, can include a band and a lip-contacting portion comprising a plurality of plastic liners, a skin healing formulation, and an ice pack gel solution filling. The face mask assembly can self-adhere to a patient's face. The skin healing formulation can include a first active botanical compound and a second active botanical compound that can function as an analgesic, an antimicrobial, an activity, an anti-inflammatory and/or an antioxidant.

The present invention provides a compound having the structure wherein A is a ring structure, with or without substitution; X1 is C or N; X2 is N, O, or S; Y1 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y 2 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y3 is H-(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y 4 is H-(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); Y5 is H, -(alkyi), -(alkenyl), -(alkynyl), -(cycloalkyi), (haloalkyi), -(alkyl)-O-(alkyl) or -(alkyl)-(cycloalkyl); a and P are each present or absent and when present each is a bond.

The present invention relates to large scale manufacture of nanoscale microsheets for use in applications such as wound healing or modification of a biological or medical surface. In some embodiments, the present invention provides devices for application to a wound comprising: a first polymer layer comprising a first bioactive agent; a second polymer layer comprising a second bioactive agent; and a third polymer layer positioned in between the first and second polymer layer so that the three polymer layers are stacked in a sandwich-type structure.

The present invention relates to a transdermal delivery system (TDS) comprising at least one dopamine agonist, wherein the at least one dopamine agonist is present in a matrix containing at least one polymer from the class of polybutylene. The present invention also relates to a method for producing the TDS according to the invention and to the use of the TDS according to the invention.